menu

Reducing the Risk of Hepatocellular Carcinoma in Hepatitis B & C

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Reducing the Risk of Hepatocellular Carcinoma in Hepatitis B & C

close
0.25 credits
15 minutes
Reducing the Risk of Hepatocellular Carcinoma in Hepatitis B & C
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Chronic hepatitis B and chronic hepatitis C are the major risk factors for hepatocellular carcinoma (HCC) in the US, and physicians often fail to follow HCC screening recommendations.  Studies show that less than 20 percent of patients at high risk for HCC ever undergo surveillance. Prognosis is typically poor when HCC is diagnosed late; survival rates of patients with advanced untreated disease are reported to be less than 6 months.  However, when identified and treated in earlier stages, HCC 5-year survival rates may approach 80 percent, underscoring the need for surveillance and screening of those at risk. The advent of direct-acting antiviral (DAA) therapies leading to reduced viral load has been a major breakthrough in reducing the risk of HCC; nonetheless, surveillance for cancer must be continued due to residual HCC risk.

    There are a number of barriers to screening and surveillance for HCC, including lack of familiarity with current guidelines, lack of information on risk stratification and appropriate screening modalities, and challenges in communicating with patients about HCC surveillance. Patients treated for hepatitis B with antiviral therapy should continue to be screened for HCC regardless of cirrhosis. Surveillance for HCC should also be continued for all hepatitis C patients with advanced fibrosis (F3) and cirrhosis, including those who have achieved SVR with DAA therapy.

  • Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Joseph Lim

    Grant/Research Support: Gilead Sciences, Allergan, Conatus Pharmaceuticals, Eiger Biopharmaceuticals, Genfit, Intercept Pharmaceuticals 

    David Bernstein

    Consultant/Independent Contractor: Gilead Sciences

    Andrew Muir                                     

    Grant/Research Support: Abbvie Inc, Gilead Sciences, Merck & Company
    Advisory Board: Abbvie Inc, Gilead Sciences

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Planner or Manager

    Reported Financial Relationship

    Ashley Marostica, RN, MSN

    Nothing to disclose

    Lindsay Borvansky

    Nothing to disclose

    Andrea Funk

    Nothing to disclose

    Liddy Knight

    Nothing to disclose

    Ashley Cann

    Nothing to disclose

    Raquel Da Rosa

    Nothing to disclose

    Joanne Jablonski

    Nothing to disclose

  • Target Audience

    Healthcare providers practicing in communities with patients at increased risk for CHB, CHC, and HCC, including gastroenterologists, hepatologists, infectious disease specialists, primary care practitioners, physician assistants, nurse practitioners, and registered nurses.

  • Learning Objective

    1. Explain current strategies for screening, diagnosis and surveillance in patients at increased risk for HCC including approaches to reducing risk for progression to HCC
  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and the Asian Health Foundation.  Global is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Global Education Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Accreditation
    Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    This educational activity for 0.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Contact Information
    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

    Term of Offering
    This activity was released on August 26, 2020 and is valid for one year. Requests for credit must be made no later than August 26, 2021.

    Fee Information& Refund/Cancellation Policy
    There is no fee for this educational activity.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Asian Health Foundation do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider

    This activity is jointly provided by Global Education Group and the Asian Health Foundation.

  • Commercial Support

    This program is supported by an unrestricted educational grant from Gilead Sciences, Inc.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Chronic hepatitis B and chronic hepatitis C are the major risk factors for hepatocellular carcinoma (HCC) in the US, and physicians often fail to follow HCC screening recommendations.  Studies show that less than 20 percent of patients at high risk for HCC ever undergo surveillance. Prognosis is typically poor when HCC is diagnosed late; survival rates of patients with advanced untreated disease are reported to be less than 6 months.  However, when identified and treated in earlier stages, HCC 5-year survival rates may approach 80 percent, underscoring the need for surveillance and screening of those at risk. The advent of direct-acting antiviral (DAA) therapies leading to reduced viral load has been a major breakthrough in reducing the risk of HCC; nonetheless, surveillance for cancer must be continued due to residual HCC risk.

    There are a number of barriers to screening and surveillance for HCC, including lack of familiarity with current guidelines, lack of information on risk stratification and appropriate screening modalities, and challenges in communicating with patients about HCC surveillance. Patients treated for hepatitis B with antiviral therapy should continue to be screened for HCC regardless of cirrhosis. Surveillance for HCC should also be continued for all hepatitis C patients with advanced fibrosis (F3) and cirrhosis, including those who have achieved SVR with DAA therapy.

  • Disclosure of Conflicts of Interest

    Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Joseph Lim

    Grant/Research Support: Gilead Sciences, Allergan, Conatus Pharmaceuticals, Eiger Biopharmaceuticals, Genfit, Intercept Pharmaceuticals 

    David Bernstein

    Consultant/Independent Contractor: Gilead Sciences

    Andrew Muir                                     

    Grant/Research Support: Abbvie Inc, Gilead Sciences, Merck & Company
    Advisory Board: Abbvie Inc, Gilead Sciences

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Name of Planner or Manager

    Reported Financial Relationship

    Ashley Marostica, RN, MSN

    Nothing to disclose

    Lindsay Borvansky

    Nothing to disclose

    Andrea Funk

    Nothing to disclose

    Liddy Knight

    Nothing to disclose

    Ashley Cann

    Nothing to disclose

    Raquel Da Rosa

    Nothing to disclose

    Joanne Jablonski

    Nothing to disclose

  • Target Audience

    Healthcare providers practicing in communities with patients at increased risk for CHB, CHC, and HCC, including gastroenterologists, hepatologists, infectious disease specialists, primary care practitioners, physician assistants, nurse practitioners, and registered nurses.

  • Learning Objective

    1. Explain current strategies for screening, diagnosis and surveillance in patients at increased risk for HCC including approaches to reducing risk for progression to HCC
  • Accreditation and Credit Designation Statements

    Physician Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and the Asian Health Foundation.  Global is accredited by the ACCME to provide continuing medical education for physicians.

    Physician Credit Designation
    Global Education Group designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nursing Accreditation
    Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    This educational activity for 0.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Contact Information
    For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

    Term of Offering
    This activity was released on August 26, 2020 and is valid for one year. Requests for credit must be made no later than August 26, 2021.

    Fee Information& Refund/Cancellation Policy
    There is no fee for this educational activity.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Asian Health Foundation do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider

    This activity is jointly provided by Global Education Group and the Asian Health Foundation.

  • Commercial Support

    This program is supported by an unrestricted educational grant from Gilead Sciences, Inc.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/23/20